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Summary 
The aim of this study was to assess the clinical, radiological and biological efficacy and tolerability of the SYSADOA, 
chondroitin 4- and 6-sulfate (CS, CondrosulP ~, IBSA, Lugano, Switzerland), in patients suffering from knee 
osteoarthritis. 
This was a 1-year, randomized, double-blind, controlled pilot study which included 42 patients of both sexes, aged 
35--78 years with symptomatic knee OA. Patients were treated orally with 800 mg chondroitin sulfate (CS) per day or 
with a placebo (PBO) administred in identical sachets. The main outcome criteria were the degree of spontaneous joint 
pain and the overall mobility capacity. Secondary outcome criteria included the actual joint space measurement and 
the levels of biochemical markers of bone and joint metabolism. 
This limited study confirmed that chondroitin sulfate was well-tolerated and both significantly reduced pain and 
increased overall mobility capacity. Treatment with CS was also associated in a limited group of patients with a 
stabilization of the medial femoro-tibial joint width, measured with a digitized automatic image analyzer, whereas joint 
space narrowing did occur in placebo-treated patients. In addition, the metabolism of bone and joint assessed by 
various biochemical markers also stabilized in the CS patients whereas it was still abnormal in the PBO patients. 
These results confirm that oral chondroitin 4- and 6-sulfate is an effective and safe symptomatic slow-acting drug 
for the treatment of knee OA. In addition, CS might be able to stabilize the joint space width and to modulate bone 
and joint metabolism. This is the first preliminary demonstration that a SYSADOA might influence the natural course 
of OA in humans. 
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Introduction 
OSTEOARTHRITIS (OA),  'an heterogeneous group of 
condit ions that  lead to joint symptoms and 
signs which are associated with defective integrity 
of art icu lar  cart i lage, in addit ion to related 
changes in the under ly ing bone and at the joint 
margins '  [1], is the most common form of arthr i t is  
encountered in developed countr ies and is highly 
prevalent  in elderly people. The diagnosis of OA is 
essential ly based upon clinical and radiological  
evidence of cart i lage destruction. Current  treat- 
ment of OA is not aimed at a cure, but at pal l iat ive 
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management;  it includes physical, pharmacologic  
and surgical  approaches.  Drug t reatments  include 
analgesics and nonsteroidal  ant i - inf lammatory 
drugs (NSAIDs), symptomat ic  slow-acting drugs 
for OA (SYSADOA) and disease-modifying OA 
drugs (DMOAD) not yet avai lable [2, 3]. Currently,  
NSAIDs are sometimes prescr ibed in OA pat ients 
to al leviate pain by reducing the ongoing 
inf lammatory processes, but their  use in OA has 
been quest ioned recently. Indeed, some studies 
showed that  NSAIDs were no more efficient than 
simple analgesics [4 6]. In addition, there is a clear 
associat ion between NSAID consumpt ion and 
gastro- intest inal  as well as renal compl icat ions 
[7-9]. For now, it remains unclear  whether  NSAIDs 
can influence the progression of OA by modifying 
the under ly ing pathology; so far there is no 
evidence that  this group of drugs has a potent ia l  
for disease-modifying act iv ity [10]. A few years ago 
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the search for alternative therapeutic solutions 
began in earnest and lead to the concept of 
slow-acting drugs for the treatment of OA 
(SADOA). These drugs have a slow onset of action 
and improve OA symptoms after a couple of weeks 
[3]. Some are administered orally while others are 
given intra-articularly [11]. Among them, the 
symptomatic slow-acting drug for OA (SYSADOA), 
chondroitin sulfate (CS), is a glycosaminoglycan 
which is naturally found in the extracellular 
matrix of articular cartilage. Previous pharma- 
cokinetic studies have shown that radiolabeled CS 
was absorbed in high proportion when given orally 
and that its concentration in synovial fluid 
increased accordingly [12,13]. Other results, 
however, have suggested that most of the intact or 
depolymerized CS was enzymatically degraded in 
the intestinal tract and therefore could not be 
re-absorbed as such [14]. Based upon previous 
studies which showed an efficacy of CS treatment 
[15, 16], we decided to test the clinical, radiological 
and biochemical effects of oral Condrosulg" (IBSA, 
Lugano, Switzerland) versus placebo in a l-year 
randomized, controlled, double-blind pilot trial in 
patients uffering from symptomatic knee OA. 
Rehabilitation as in- or out-patients. They suffered 
from mono- or bilateral clinically symptomatic 
knee OA with a minimum remaining femoro-tibial 
joint space of 25% on standard X-ray (Table I). All 
patients uffering from inflammatory or systemic 
diseases, or conditions involving the joints, such 
as primary or secondary neoplasias, bone meta- 
bolic diseases, and/or other metabolic or systemic 
diseases, lower limbs axial deviation > 5 degrees, 
and treatments such as steroids or bone-oriented 
treatments less than 3 months before entering the 
study were excluded from the study. Patients from 
the CS group received two sachets, each contain- 
ing 400 mg of sodium chondroitin 4- and 6-sulfate 
(Condrosuli~% IBSA) per day, dissolved in half a 
glass of water, for a total duration of 1 year. 
Patients from the matched PBO group received the 
same daily amount of the vehicle (sorbitol, citric 
acid, saccharin sodium, orange flavour, beta- 
carotene) alone. The patients had free access to 
paracetamol as a rescue medication whose intake 
was not limited. The study was approved by the 
Ethical Committee of the University Hospital of 
Geneva and conducted according to the Declara- 
tion of Helsinki. 
Pat ients  and  Methods  
PATIENTS, RANDOMIZATION, PRETREATMENT TESTS 
AND TREATMENT 
A total of 60 patients were initially seen; a total 
of 46 aged 35 78 were admitted into the trial (22 
men and 24 women) and enrolled in a 1-year 
randomized, controlled clinical trial and assigned 
to one of the following groups: CS-treated or 
matched placebo-treated (PBO). All patients were 
referred to the Division of Physical Medicine and 
CLINICAL EVALUATION 
The main outcome criteria were the degree of 
spontaneous joint pain, which was assessed using 
the Huskisson Visual Analogue Scale (VAS) [17], 
and the overall mobility capacity by a VAS at entry 
and at months 3, 6 and 12. 
Besides, secondary outcome criteria included 
the actual joint space measurement and some 
biochemical markers: standard weight-bearing 
antero-posterior X-rays of the knee joint in 
extension were taken upon entry and at the end of 
Table I 
Patients characteristics at entry (m _+ S.D.) 
Group CS (n = 23) PBO (n = 23) 
Age (years) ' 60 + 13 57 + 11 
range (35 78) (37-76) 
Sex (M/F) 12/11 10/13 
Weight (kg) 72 + 11 76 + 14 
range (56-98) (52-102) 
Size (cm) 168 + 7 167 + 7) 
range (15~182) (157-180) 
Radiological stage according to Kellgren and Lawrence 
Stage 0 0 0 
Stage I 10 11 
Stage II 11 10 
Stage III 2 2 
Stage IV 0 0 
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the study. All X-rays were taken by the same 
technician and all efforts were made to standardize 
the position of the patient during the examin- 
ations. Both knees were X-rayed but only the most 
damaged was taken into account for the inclusion 
and follow-up. Analyses were performed by an 
external radiologist who evaluted the Kellgren 
and Lawrence score. Regarding the joint space 
measurement, he radiographs were measured 
blindly by one observer (MP) without knowledge of 
radiographic grade, with an image analysis 
computer (Mediscan, Hologic) using aprogram 
derived from a hip measurement program pre- 
viously developed by T. Conrozier [18]: the film was 
placed on the viewbox and digitized at a resolution 
of 512/512 pixel, with 256 levels of grey. The 
digitized image was then automatically modified by 
the computer (subtraction and • 2 magnification) to
obtain a very clear outline of the femorotibial joint 
space (FTJS). A constant part of FTJS was 
automatically determined from two peripheral 
points (the two tibial plateau ends for the medial 
compartment measurement and the two femoral 
condyle ends for lateral compartment measure- 
ment) and a 172 ~ constant angle. Within the 
demarcated area, the joint space contours were 
delineated on the margin of the femoral condyle 
and the margin of the tibial plateau. The joint 
surface area (JSA) and the mean joint space width 
(MJSW) were then automatically calculated. 
Interbone distance at the narrowest point of the 
joint [minimum joint space narrowing (MJSN)] 
was calculated by the computer from a given point. 
The reproducibility ofthis method was assessed by 
the blind measurement of ten knee OA films 
selected at random, each film read by three 
different observers and five times by the same 
observer. The method of measurement also had 
good intra-observer reproducibility: CV was 3.34% 
for JSA, 5.14% for MJSW and 5% for MJSN. 
Interobserver reproducibility was less satisfactory: 
CV swere 18.7%, 13.8% and 16.9% respectively (E. 
Vignon et al., personal unpublished results). 
The following biochemical markers of bone 
and joint metabolism were measured at entry and 
at months 3, 6 and 12. Serum osteocalcin (OC), a 
marker of bone formation, was measured by 
immunoradiometry using the ELSA-OSTEO R kit 
(CISBio International, Inc.) [19]. OC levels are 
given in ng/ml. Serum antigenic keratan sulfate 
(KS), a marker of the degradation of aggrecan, the 
major cartilage proteoglycan, was quantified by a 
competitive inhibition ELISA using thel/20/5-D-4 
anti-KS monoclonal antibody [20]. KS is expressed 
in ng/ml. Total urinary pyridinoline (Pyr) an 
deoxy-pyridinoline (D-Pyr), markers of bone and 
connective tissue degradation, were measured in 
2nd void urine samples by reversed-phase high- 
pressure liquid chromatograpy (RP-HPLC) as 
described previously [21]. All results were given in 
nmol/1 and corrected for urinary creatinine levels 
(nmol/mmol). 
Clinical tolerability was assessed at months 1, 3, 
6 and 12 using a 4-point verbal semiquantitative 
judgment score; a biological survey including 
hepatic, renal and hematological tests was con- 
ducted at the same time in each patient. 
STATISTICAL EVALUATION 
Statistical analysis of the data was performed by 
an independent Institute of Biostatistics (IBIS 
Informatica & Idee S. R. L., Milan, Italy) using the 
BioMeDical Programs(BMDP R) package (BMDP 
Statistical Software, Cork Technology Park, 
Model Farm, Cork, Ireland). Analysis of variance 
and covariance for repeated measures as well as 
the Student's t-test were used for the parametric 
variables, while the Pearson chi-square test was 
used for analyzing the categorical type of 
variables. Only results with P < 0.05 were con- 
sidered as significant. 
Resu l ts  
The drop-out rate was 8.7% in both CS and PBO 
groups, and a total of 42 patients, matched for sex, 
age, body weight and size, completed the l-year 
study course. The reasons for dropping out are 
listed in Table II. 
MAIN OUTCOME MEASURES 
Pain  
All patients of both groups complained of knee 
joint pain and no statistically significant differ- 
ence was observed between the two groups upon 
entry. Based upon the Huskisson VAS (range: 
0 10 cm), the level of pain was 5.76 _+ 1.61 cm in the 
CS group vs 6.44 +_ 1.10 cm in the PBO group upon 
entry. At month 3, there was a 37% decrease in 
joint pain in the CS group as compared to 19% in 
Table II 
Reasons for drop-outs 
Group CS (n=23) PBO (n=23) 
Death 1 F -- 
Left the country 1 F 1 M 
Not satisfied -- 1 M 
Total 2 F 2 M 
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Table III 
Spontaneous joint pain VAS in cm (m • S.D.) 
Time (month) CS PBO AOV 
0 5.8 • 1.6 6.4 • 1.1 between treatments 
3 3.6 • 2.3 5.2 • 1.5 P < 0.001 
6 2.5 • 2.1 4.8 • 1.9 between times 
12 2.1 • 2.1 4.8 • 2.5 P < 0.05 
the PBO group (Mann-Whitney between groups: 
P < 0.05 in favor of CS) (Table III). This difference 
between both groups became more marked at 
month 12 with an overall  decrease in the CS group 
of 63% corresponding to 2.13 • 2.15 cm vs 26% 
corresponding to 4.79 + 2.52 cm in the PBO group 
(Mann-Whitney between groups: P < 0.01 in favor 
of CS group). The difference in pain level between 
entry and month 12 was significant only in the CS 
group (Wilcoxon: P < 0.01). There was a statisti- 
cally significant difference also with the AOV 
analysis (between treatments: P < 0.001, between 
times: P < 0.05). 
Overall mobility capacity 
Upon entry, all patients presented with a 
reduct ion of nearly 50% of their  overall  mobil ity 
capacity (VAS levels: 5.08 + 1.55cm in the 
CS group vs 5.71_ 1.62cm in the PBO group) 
but no signif icant difference between both 
groups was observed (Table IV). At month 3, 
there was a moderate increase in both groups 
which became more marked and significant 
by month 6 (+45% in CS vs +17% in PBO, 
Mann-Whitney between groups: P < 0.01). 
The overal l  mobil ity capacity after one year 
increased by 69% in the CS group as compared to 
only 19% in the PBO group (Mann-Whitney 
between groups: P<0.01) .  The difference in 
funct ional  capacity level between entry and month 
12 was signif icant only in the CS group (Wilcoxon: 
P < 0.01). 
SECONDARY OUTCOME MEASURES 
Radiological evolution 
On a qual itat ive basis, the Kel lgren and 
Lawrence radiological score did not differ signifi- 
cantly between entry and month 12 time point in 
either the CS or the PBO group. On a quant i tat ive 
perspective, serial radiographs (baseline and 12 
month) were available for only 14 patients in the 
CS group and 12 in the PBO group, and the 
following findings were obtained with respect to 
the actual medial femoro-tibial jo int (MFTJ) space 
measured by chondrometry.  At entry, both the 
MFTJ  minimum width, mean width and surface 
area were not significantly different between the 
two groups; however, by the end of the study period 
at month 12, the MFT J  mean width had decreased 
significantly in the PBO group (paired t-test basal 
vs end control: P < 0.05), but not in the CS group. 
A similar trend was observed for the MFTJ  surface 
area, and it was at the limit of the significance 
(paired t-test: basal vs end control: P= 0.056); there 
was no significant var iat ion in the MFTJ  minimum 
width. Importantly,  when the differences in per 
cent between month 12 and entry of the individual 
values of both CS and PBO group patients were 
addressed, a statistical ly significant difference in 
favor of the CS group was found for all measured 
parameters (MFTJ  minimum width, mean width 
and surface area, Student's t-test: P < 0.01). The 
MFTJ  space decreased in the PBO group, whereas 
no modification was present in the CS group over 
1 year of follow-up (Table V). 
Table IV 
Overall mobility capacity VAS in cm (m • S.D.) 
Time (month) CS PBO AOV 
0 5.1 • 1.5 5.7 + 1.6 between treatments 
3 5.5 + 2.3 6.5 • 1.9 P=ns 
6 7.5 • 1.9 6.7 • 1.9 between times 
12 8.6 • 1.4 6.8 • 2.3 P < 0.001 
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Table V 
Quantitative assessment of the medial femoro-tibial 
joint space narrowing using a digitized automatic image 
analyzer 







Medial femoro-tibial joint minimum width (cm) 
0.34 • 0.10 0.40 • 0.10 
0.35 + 0.10 0.36 + 0.13 
Medial femoro-tibial joint mean width (cm) 
0.44 • 0.11 0.51 • 0.10 
0.44 • 0.10 0.46 • 0.14" 
Medial femoro-tibial joint surface area (cm'-') 
1.08 _+ 0.32 1.29 • 0.28 
1.09 • 0.33 1.17 • 0.36t 
*P < 0.05 (paired t-test vs end control). 
tP = 0.056 (paired t-test vs end control). 
Biological evaluation (Table VI) 
Serum osteocalcin (OC) was measured in a 
total  of 41 pat ients (21 CS; 20 PBO). At entry 
both groups had no signif icantly different 
levels of OC (CS = 16 • 7 ng/ml, PBO = 21 • 13 ng/ 
ml); during the evolution, there were no signif icant 
var iat ions in the CS group. In the PBO group, OC 
levels showed a cont inuous trend toward an 
increase which peaked at 12 months. When OC 
levels are expressed in A% between month 12 and 
entry, there was a signif icant difference between 
both groups with a 24.4% increase in the PBO 
group and a 1.4% decrease in the CS group, (AOV 
between treatments:  P < 0.001). 
Serum ant igenic KS was measured in the serum 
of 21 CS and 19 PBO patients. At entry, both 
groups had comparable  levels of ant igenic KS 
(CS = 449 • 119 ng/ml, PBO = 386 • 133 ng/ml). In- 
itial levels of ant igenic KS were clearly elevated in 
both groups when compared to previously pub- 
l ished [20] serum KS levels of age-matched controls 
(268• 133ng/ml). Levels of ant igenic KS de- 
creased by 6.6% after 12 months in the CS group, 
whereas it increased by 4.4% in the PBO group. 
Fr iedman two-way AOV calculated on the A% 
between month 12 and entry showed a stat ist ical ly 
signif icant difference between the two groups 
(P < 0.001). 
Ur inary  Pyr/cr. levels were similar in the 
two groups at entry (CS=56+ 25nmol/mmol;  
PBO=59 •  Between entry and 
month 12, in the CS group a 10% decrease in 
ur inary Pyr/cr. levels was observed, whereas a 33% 
increase was observed in the PBO group. Over the 
12 months of the study, the A% Pyr/cr. between 
month 12 and entry showed a stat ist ical ly 
signif icant difference between the treatment-  
groups, P < 0.001, using the Fr iedman two-way 
AOV. The PBO pat ients clearly showed an 
increased catabol ic response in terms of col lagen 
breakdown. 
Ur inary  D-Pyr/cr. levels were comparable in 
both groups at entry (CS--7.7 • 3.0 nmol/mmol; 
PBO=8.5  • 5.4nmol/mmol).  There was a 11.5% 
decrease in ur inary D-Pyr/cr. levels in the CS 
group, whereas D-Pyr/cr. excret ion increased by 
57.3% in the PBO group over i year of follow-up. 
Fr iedman two-way AOV applied to the A% 
D-Pyr/cr. between month 12 and entry showed a 
stat ist ical ly signif icant difference between the two 
t reatment  groups (P < 0.001). Again, the PBO 
group showed a dramat ic  increase in type I 
col lagen breakdown products mostly derived from 
bone tissue, whereas this did not happen in the CS 
group. 
Tolerability 
Overal l  to lerabi l i ty of the test drug as well as the 
placebo, expressed by both the physic ian and the 
patient,  was good (chi-square: P = ns). Compar ison 
of cl inical side-effects revealed no signif icant 
difference between the two groups at any time of 
Table VI 
Evolution of biochemical markers of bone and cartilage metabolism (m • S.D.) 
CS PBO AOVt 
Marker Entry Month 3 Month 6 Month 12 Entry Month 3 Month 6 Month 12 (P) 
Osteocalcin 16 + 7 16 + 5 17 + 7 16 + 6 21 + 13 20 + 14 22 • 18 26 + 29 < 0.001 
(ng/ml) 
Keratansulfate 449• 423• 411• 420• 386• 408• 389• 403• <0.001 
(ng/ml) 
Pyridinoline/cr. 56 • 25 52 • 22 54 • 31 53 • 19 59 • 40 60 • 30 74 • 46 70 • 30 < 0.001 
(nmol/mmol) 
Deoxy- 7.7 • 3.0 7.1 • 2.6 7.2 • 3.9 7.0 • 2.3 8.5 • 5.4 9.3 _+ 4.5 12.0 • 8.8 11.7 • 8.1 0.001 
pyridinoline/cr. 
(nmol/mmol) 
~Friedman two-way AOV carried out between treatments on the A%, values between entry and month 12. 
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the study period. In addition, the biologic 
tolerability was also excellent in both groups: 
blood, renal and liver biological parameters did 
not differ significantly between the groups during 
the study period (AOV: P= ns). 
Discuss ion  
This 1-year andomized, double-blind, controlled 
study showed that the drug was clinically and 
biologically well-tolerated and significantly re- 
duced pain due to OA, while simultaneously 
increasing overall mobility of the patients. It was 
also able to stabilize the medial femoro-tibial joint 
space in a limited number of patients and modulate 
the expression of various markers of bone and 
cartilage metabolism. 
While NSAIDs have proved helpful for the 
symptomatic relief of acute painful OA, the 
slow-acting symptomatic drugs (SADOAs) are 
agents that can alleviate OA symptoms for the 
longer term and in a safer way but with a delayed 
onset of action. Among them, a lot of natural and 
synthetic ompounds of various origins have been 
introduced on the market, but only a few have been 
proven to be effective in reducing OA symptoms, 
i.e., pentosan polysulfate, high-molecular-weight 
hyaluronan, diacerrhein and chondroitin sulfate 
[11 22]. CS, a glycosaminoglycan chain made up of 
the repeating disaccharide [D-glucuronic acid-N- 
acetylgalactosamine sulfated at the 4 or 6 position] 
is a major constituent of cartilaginous tissues [23]. 
One rationale for using this type of compound in 
OA is based upon the fact that it has been 
demonstrated that OA cartilage becomes progress- 
ively depleted of this glycosaminoglycan [24 26]. 
Oral administration of CS has received less 
attention, in part because CS is thought to be 
degraded quite effectively in the digestive tract 
[26] but also because metabolites of the orally 
administered CS chains have not been clearly 
identified so far in blood plasma [14]. On the 
contrary, the unmodified CS chains with an 
integral sulfation degree have been identified in 
plasma. 
While the exact mechanism of action of oral CS 
remains unknown, recent controlled studies have 
suggested a delayed analgesic effect of oral CS in 
OA patients [28]. The recent development of 
radiological methods capable of measuring actual 
changes in knee joint space has led to a significant 
improvement in the follow-up of OA patients. 
Using high-definition micro-focal radiography [29], 
Buckland-Wright showed that joint space width 
measurement was a good predictor of cartilage 
thinning and compression in OA of the medial 
compartment of the knee [30]. Using a computer- 
ized image analysis system with digitally stored 
radiographs, other authors were able to quantify 
joint space narrowing in both hip and knee OA 
[18, 31, 32]. Using this digitized automatic analysis 
to measure the evolution of medial femoro-tibial 
joint space, we were able to show that in a limited 
group of patients receiving chondroitin sulfate 
orally the actual joint space did not change over a 
period of 1 year, while in some PBO patients it 
narrowed. However, these good results should be 
considered very carefully as the small number of 
X-rays available for chondrometry might have 
introduced a bias, picking up these patients with 
the more severe change at entry in the PBO group 
or chance differences in progressors in both PBO 
and CS groups. Molecules derived from the 
turnover of cartilage and bone macromolecules are 
present in body fluids and have been shown to 
provide a measure of the metabolic changes that 
take place in these tissues in osteoarthritis [33]. 
The observation that levels of serum antigenic KS, 
serum OC and urinary D-Pyr all underwent a 
significant decrease as a result of treatment with 
CS are worth noting as they suggest hat the drug 
had an effect on the metabolism of cartilage 
(antigenic KS) and bone (OC and D-Pyr). Although 
the decrease in the serum level of antigenic KS in 
the CS group was relatively minor, it is most 
interesting as several studies of human adults have 
repeatedly shown that the serum level of this 
marker of the degradation of the cartilage 
proteoglycan, aggrecan, is very stable during the 
day and from year to year and that it is not affected 
by treatment with NSAIDs or analgesics [34, 35]. 
The contention that the drug did indeed have an 
effect on the metabolism of bone gains strength 
from the finding that levels of serum OC and 
urinary D-Pyr both rose in the PBO group. The CS 
induced decrease in the levels of these markers of 
bone turnover may indicate that the drug has an 
effect on the subchondral bone by inhibiting the 
degradation of the collagenous meshwork. 
To our knowledge, this is the first demonstration 
that a slow-acting drug for the symptomatic 
treatment of knee OA might be additionally 
capable of influencing the natural course of the 
disease. Further trials, including more patients 
and over longer periods of time, are definitively 
necessary to confirm the possible structure-modify- 
ing properties of this SADOA drug. 
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